Cargando…

Interferon beta-1b for COVID-19

Detalles Bibliográficos
Autor principal:	Shalhoub, Sarah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211497/ https://www.ncbi.nlm.nih.gov/pubmed/32401712 http://dx.doi.org/10.1016/S0140-6736(20)31101-6

Ejemplares similares

Nebulised interferon beta-1a for patients with COVID-19
por: Peiffer-Smadja, Nathan, et al.
Publicado: (2021)

Subcutaneous interferon beta-1a in COVID-19: raking the ashes of an intervention trial
por: Wilkinson, Tom
Publicado: (2021)

PIONEER trial: favipiravir to treat moderate COVID-19
por: Shalhoub, Sarah
Publicado: (2023)

Type I interferon, anti-interferon antibodies, and COVID-19
por: Calabrese, Leonard H, et al.
Publicado: (2021)

Dysregulation of type I interferon responses in COVID-19
por: Acharya, Dhiraj, et al.
Publicado: (2020)

The type I interferon response in COVID-19: implications for treatment
por: Lee, Jeong Seok, et al.
Publicado: (2020)

Could Beta variant containing COVID-19 booster vaccines tackle Omicron variants?
por: Jin, Pengfei, et al.
Publicado: (2023)

The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022
por: Sridhar, Saranya, et al.
Publicado: (2022)

Not just antibodies: B cells and T cells mediate immunity to COVID-19
por: Cox, Rebecca J., et al.
Publicado: (2020)

Effectiveness of BNT162b2 against COVID-19 in adolescents
por: Powell, Annabel A, et al.
Publicado: (2022)

Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era
por: Wang, Stephen Y, et al.
Publicado: (2022)

Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19
por: Richardson, Christopher D
Publicado: (2021)

Beta SARS-CoV-2 variant and BNT162b2 vaccine effectiveness in long-term care facilities in France
por: Lefèvre, Benjamin, et al.
Publicado: (2021)

Comparing the outcomes of treatment with INF-β 1-a (interferon beta-1a) and IFN-β 1-b (interferon beta-1b) among COVID-19 inpatients
por: Seyfi, Shahram, et al.
Publicado: (2021)

COVID-19 pneumonia and the appropriate use of antibiotics
por: Ginsburg, Amy Sarah, et al.
Publicado: (2020)

COVID-19 and disparities affecting ethnic minorities
por: Morales, Daniel R, et al.
Publicado: (2021)

Reassurance on bleeding and thrombotic events following second dose BNT162b2 and ChAdOx1 COVID-19 vaccines
por: Pavord, Sue, et al.
Publicado: (2023)

Severe COVID-19 pneumonitis and timing of birth in women
por: Calvert, Clara, et al.
Publicado: (2023)

The pivotal role of the angiotensin-II–NF-κB axis in the development of COVID-19 pathophysiology
por: Okamoto, Hiroshi, et al.
Publicado: (2020)

The right place for IL-1 inhibition in COVID-19
por: Cavalli, Giulio, et al.
Publicado: (2021)

Transmission of Omicron (B.1.1.529) - SARS-CoV-2 Variant of Concern in a designated quarantine hotel for travelers: a challenge of elimination strategy of COVID-19
por: Wong, Shuk-Ching, et al.
Publicado: (2021)

Considerations of hybrid immunity and the future of adolescent COVID-19 vaccination
por: Irving, Stephanie A, et al.
Publicado: (2023)

The network effect: studying COVID-19 pathology with the Human Cell Atlas
por: Teichmann, Sarah, et al.
Publicado: (2020)

COVID-19 highlights the model dilemma in biomedical research
por: Adhikary, Partho Protim, et al.
Publicado: (2021)

COVID-19 vaccination in patients with α1-antitrypsin deficiency
por: Yang, Chengliang, et al.
Publicado: (2021)

Key ethical questions for research during the COVID-19 pandemic
por: Townsend, Ellen, et al.
Publicado: (2020)

Covid19 Outbreak in Victoria, Australia Update August 1, 2020
por: Boretti, Alberto
Publicado: (2020)

A role for interleukin-1 receptor antagonism in severe COVID-19?
por: Tattersall, Rachel S, et al.
Publicado: (2021)

If not now, when? COVID-19, lived experience, and a moment for real change
por: Jones, Nev, et al.
Publicado: (2020)

High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19
por: So-Osman, Cynthia, et al.
Publicado: (2022)

Understanding why superspreading drives the COVID-19 pandemic but not the H1N1 pandemic
por: Chen, Paul Z, et al.
Publicado: (2021)

Encouraging results from phase 1/2 COVID-19 vaccine trials
por: Bar-Zeev, Naor, et al.
Publicado: (2020)

α1-Antitrypsin deficiency and the risk of COVID-19: an urgent call to action
por: Yang, Chengliang, et al.
Publicado: (2021)

Exosomal miR-19b-3p communicates tubular epithelial cells and M1 macrophage
por: Wang, Zhi-wei, et al.
Publicado: (2019)

Role of interferon-induced GTPases in leishmaniasis
por: Lipoldová, Marie, et al.
Publicado: (2022)

COVID-19 is not influenza
por: Petersen, Eskild
Publicado: (2021)

Anticoagulation in COVID-19
por: Bradbury, Charlotte A, et al.
Publicado: (2022)

COVID-19, type 1 diabetes, and technology: why paediatric patients are leading the way
por: Danne, Thomas, et al.
Publicado: (2020)

The growing threat of wild poliovirus 1 and vaccine-derived cases in the COVID-19 era
por: Franco-Paredes, Carlos, et al.
Publicado: (2022)

Can COVID-19 changes reduce stigma in African HIV clinics?
por: Lofgren, Sarah M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b791k9ipsvq6trk1nivr4o0h9o